BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1464 related articles for article (PubMed ID: 9589666)

  • 1. Biochemical assessment of Cushing's disease in patients with corticotroph macroadenomas.
    Katznelson L; Bogan JS; Trob JR; Schoenfeld DA; Hedley-Whyte ET; Hsu DW; Zervas NT; Swearingen B; Sleeper M; Klibanski A
    J Clin Endocrinol Metab; 1998 May; 83(5):1619-23. PubMed ID: 9589666
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and biochemical characteristics of adrenocorticotropin-secreting macroadenomas.
    Woo YS; Isidori AM; Wat WZ; Kaltsas GA; Afshar F; Sabin I; Jenkins PJ; Monson JP; Besser GM; Grossman AB
    J Clin Endocrinol Metab; 2005 Aug; 90(8):4963-9. PubMed ID: 15886242
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness versus efficacy: the limited value in clinical practice of high dose dexamethasone suppression testing in the differential diagnosis of adrenocorticotropin-dependent Cushing's syndrome.
    Aron DC; Raff H; Findling JW
    J Clin Endocrinol Metab; 1997 Jun; 82(6):1780-5. PubMed ID: 9177382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adrenocorticotropin and cortisol hyperresponsiveness to hexarelin in patients with Cushing's disease bearing a pituitary microadenoma, but not in those with macroadenoma.
    Arvat E; Giordano R; Ramunni J; Arnaldi G; Colao A; Deghenghi R; Lombardi G; Mantero F; Camanni F; Ghigo E
    J Clin Endocrinol Metab; 1998 Dec; 83(12):4207-11. PubMed ID: 9851753
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cushing's disease: a comparison of pituitary corticotroph microadenomas and macroadenomas.
    Selvais P; Donckier J; Buysschaert M; Maiter D
    Eur J Endocrinol; 1998 Feb; 138(2):153-9. PubMed ID: 9506858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparisons between macroadenomas and microadenomas in Cushing's disease: characteristics of hormone secretion and clinical outcomes.
    Hwang YC; Chung JH; Min YK; Lee MS; Lee MK; Kim KW
    J Korean Med Sci; 2009 Feb; 24(1):46-51. PubMed ID: 19270812
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impaired processing of proopiomelanocortin in corticotroph macroadenomas.
    Gibson S; Ray DW; Crosby SR; Dornan TL; Jennings AM; Bevan JS; Davis JR; White A
    J Clin Endocrinol Metab; 1996 Feb; 81(2):497-502. PubMed ID: 8636257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Corticotropin-releasing hormone stimulation following low-dose dexamethasone administration. A new test to distinguish Cushing's syndrome from pseudo-Cushing's states.
    Yanovski JA; Cutler GB; Chrousos GP; Nieman LK
    JAMA; 1993 May; 269(17):2232-8. PubMed ID: 8386285
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes of therapy for Cushing's disease due to adrenocorticotropin-secreting pituitary macroadenomas.
    Blevins LS; Christy JH; Khajavi M; Tindall GT
    J Clin Endocrinol Metab; 1998 Jan; 83(1):63-7. PubMed ID: 9435417
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acquired prolactin deficiency (APD) after treatment for Cushing's disease is a reliable marker of irreversible severe GHD but does not reflect disease status.
    Mukherjee A; Murray RD; Teasdale GM; Shalet SM
    Clin Endocrinol (Oxf); 2004 Apr; 60(4):476-83. PubMed ID: 15049963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Undetectable postoperative cortisol does not always predict long-term remission in Cushing's disease: a single centre audit.
    Yap LB; Turner HE; Adams CB; Wass JA
    Clin Endocrinol (Oxf); 2002 Jan; 56(1):25-31. PubMed ID: 11849243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discriminatory value of the low-dose dexamethasone suppression test in establishing the diagnosis and differential diagnosis of Cushing's syndrome.
    Isidori AM; Kaltsas GA; Mohammed S; Morris DG; Jenkins P; Chew SL; Monson JP; Besser GM; Grossman AB
    J Clin Endocrinol Metab; 2003 Nov; 88(11):5299-306. PubMed ID: 14602765
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Study and Systematic Review of Pituitary Microadenomas vs. Macroadenomas in Cushing's Disease: Does Size Matter?
    Akirov A; Shimon I; Fleseriu M; Dotan I; Manisterski Y; Aviran-Barak N; Nadler V; Alboim S; Shochat T; Tsvetov G; Hirsch D
    J Clin Med; 2022 Mar; 11(6):. PubMed ID: 35329884
    [No Abstract]   [Full Text] [Related]  

  • 14. Diagnosis and management of Cushing's syndrome: results of an Italian multicentre study. Study Group of the Italian Society of Endocrinology on the Pathophysiology of the Hypothalamic-Pituitary-Adrenal Axis.
    Invitti C; Pecori Giraldi F; de Martin M; Cavagnini F
    J Clin Endocrinol Metab; 1999 Feb; 84(2):440-8. PubMed ID: 10022398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term results of treatment in patients with ACTH-secreting pituitary macroadenomas.
    Cannavò S; Almoto B; Dall'Asta C; Corsello S; Lovicu RM; De Menis E; Trimarchi F; Ambrosi B
    Eur J Endocrinol; 2003 Sep; 149(3):195-200. PubMed ID: 12943521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Significant gene expression of insulin-like growth factor II and proliferating cell nuclear antigen in a rapidly growing recurrent pituitary acth-secreting adenoma.
    Hashimoto K; Nagano I; Asaba K; Inoue M; Nishioka T; Takao T; Nakajo T; Mori T; Kurisaka M; Otsuka F
    Horm Res; 2000; 54(4):198-202. PubMed ID: 11416238
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FSH-producing macroadenoma associated in a patient with Cushing's disease.
    Oyama K; Yamada S; Hukuhara N; Hiramatsu R; Taguchi M; Yazawa M; Matsuda A; Ohmura E; Imai Y
    Neuro Endocrinol Lett; 2006 Dec; 27(6):733-6. PubMed ID: 17187002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metyrapone pre-treated inferior petrosal sinus sampling in the differential diagnosis of ACTH-dependent Cushing's syndrome.
    Cuneo RC; Lee W; Harper J; Mitchell K; Ward G; Atkinson RL; Salkield I; Cameron DP
    Clin Endocrinol (Oxf); 1997 May; 46(5):607-18. PubMed ID: 9231057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Comparison between the value of urinary free cortisol and 17-hydroxycorticosteroids for the diagnosis of Cushing's syndrome].
    Billon-Rey S; Beylot M; Mathian B; Patricot MC; Berthezene F; Mornex R; Revol A
    Presse Med; 1986 May; 15(21):965-8. PubMed ID: 2942852
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of the standard high dose dexamethasone suppression test and the overnight 8-mg dexamethasone suppression test for the differential diagnosis of adrenocorticotropin-dependent Cushing's syndrome.
    Dichek HL; Nieman LK; Oldfield EH; Pass HI; Malley JD; Cutler GB
    J Clin Endocrinol Metab; 1994 Feb; 78(2):418-22. PubMed ID: 8106630
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 74.